Nivolumab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13052 publications

Immunotherapy Response in Microsatellite Instability-High Gastroesophageal Adenocarcinoma.

Immunotherapy Response in Microsatellite Instability-High Gastroesophageal Adenocarcinoma.

Journal: JAMA surgery

Published: April 15, 2026

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

Journal: JAMA network open

Published: April 15, 2026

A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer).

A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer).

Journal: Future oncology (London, England)

Published: April 15, 2026

Update on pleural mesothelioma.

Update on pleural mesothelioma.

Journal: Current opinion in pulmonary medicine

Published: April 15, 2026

Cost of care and budget impact of novel first-line treatments in patients with locally advanced or metastatic urothelial carcinoma from the Colombian healthcare system perspective.

Cost of care and budget impact of novel first-line treatments in patients with locally advanced or metastatic urothelial carcinoma from the Colombian healthcare system perspective.

Journal: Expert review of pharmacoeconomics & outcomes research

Published: April 14, 2026

Effectiveness and safety of first-line nivolumab-ipilimumab in metastatic renal cell carcinoma.

Effectiveness and safety of first-line nivolumab-ipilimumab in metastatic renal cell carcinoma.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: April 13, 2026

Comparative pharmacovigilance signals for PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitor-associated hemophagocytic lymphohistiocytosis in the FAERS database.

Comparative pharmacovigilance signals for PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitor-associated hemophagocytic lymphohistiocytosis in the FAERS database.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: April 13, 2026

Unresectable advanced gastric cancer in which tumor shrinkage persisted for a long period even after the discontinuation of nivolumab third-line treatment due to immune-related adverse events:a case report

Unresectable advanced gastric cancer in which tumor shrinkage persisted for a long period even after the discontinuation of nivolumab third-line treatment due to immune-related adverse events:a case report

Journal: Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology

Published: April 12, 2026

Practice-Changing Trials in Gastrointestinal Cancers at ASCO 2025: A Critical Review and Clinical Context.

Practice-Changing Trials in Gastrointestinal Cancers at ASCO 2025: A Critical Review and Clinical Context.

Journal: Cancer investigation

Published: April 10, 2026

Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.

Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.

Journal: JCO global oncology

Published: April 10, 2026

Efficacy of Ipilimumab and Nivolumab Rechallenge in a Long-Term Melanoma Survivor: A Case Report.

Efficacy of Ipilimumab and Nivolumab Rechallenge in a Long-Term Melanoma Survivor: A Case Report.

Journal: The American journal of case reports

Published: April 09, 2026

Correction: Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population.

Correction: Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population.

Journal: Cancer immunology, immunotherapy : CII

Published: April 06, 2026

Showing 1-12 of 13,052

Last Updated: 04/28/2026